FDA Inspection 1166989 — Global Blood Therapeutics, Inc.
The FDA completed an inspection of Global Blood Therapeutics, Inc. on March 11, 2022 in South San Francisco, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 11, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- South San Francisco, CA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)